|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
TYK2 kinase inhibitors - Pipeline Insight, 2022 ... deucravacitinib in Phase 3 clinical studies in psoriasis. Brepocitinib: Pfizer Brepocitinib (PF-06700841) is a selective topical, tyrosine ... Products Baricitinib Deucravacitinib OST-122 Brepocitinib GLPG-3121 FTP 637 SDC ... Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 ... Global Uveitis Treatment Market - 2025 -2033 ... in the CLARITY Phase 3 study for brepocitinib in non-anterior non-infectious uveitis ... . The FDA has granted Brepocitinib Fast Track Designation for NIU ... Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019 Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019 SUMMARY Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by ... Crohn’s Disease - Pipeline Insight, 2021 ... TAK-018 SGX203 IMU 838 Brepocitinib Alicaforsen Bacteroides thetaiotaomicron BT-11 JNJ-64304500 ... Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs In Development, 2022, provides ... Dermatomyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major dermatomyositis markets reached a value of US$ 192.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 278.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2024-2034. The dermatomyositis market has ... |